Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Acalabrutinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Acalabrutinib as a study intervention. Browse Acalabrutinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
127
Shown on this page
12
Current sort
Recently updated
Therapy scope
Acalabrutinib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Acalabrutinib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 109–120 of 127 matching trials for Acalabrutinib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Calcium carbonate, Omeprazole, Rifampin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

NCT04905043
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, SmartPill®
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

NCT04901923
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Itraconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

NCT04876807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Omeprazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
19 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

NCT04867941
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03205046
View directory record Official record
Conditions
DLBCL, Richter Syndrome
Interventions
acalabrutinib, vistusertib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Fairway, Kansas • Bethesda, Maryland • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797
View directory record Official record
Conditions
Infectious Disease
Interventions
Acalabrutinib, Rabeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

NCT02211014
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

NCT04435483
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability
Interventions
Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 19, 2026, 6:33 PM EDT

About this Acalabrutinib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Acalabrutinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acalabrutinib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Acalabrutinib.